MEA Age-Related Updated Macular Degeneration (AMD) Disease - ANTI VEGF Market - Industry Trends and Forecast to 2034

TABLE OF CONTENTS

1 INTRODUCTION 13

• 1.1 OBJECTIVES OF THE STUDY 13
• 1.2 MARKET DEFINITION 13
• 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET 13
• 1.4 LIMITATIONS 15
• 1.5 MARKETS COVERED 15

2 MARKET SEGMENTATION 17

• 2.1 MARKETS COVERED 17
• 2.2 GEOGRAPHICAL SCOPE 18
• 2.3 YEARS CONSIDERED FOR THE STUDY 19
• 2.4 CURRENCY AND PRICING 19
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 20
• 2.6 MULTIVARIATE MODELLING 23
• 2.7 TYPE LIFELINE CURVE 24
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
• 2.9 DBMR MARKET POSITION GRID 26
• 2.10 MARKET END USER COVERAGE GRID 27
• 2.11 VENDOR SHARE ANALYSIS 28
• 2.12 SECONDARY SOURCES 29
• 2.13 ASSUMPTIONS 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 32

• 4.1 PESTEL 33
• 4.2 PORTERS_ 34
• 4.3 PRICING ANALYSIS 35
• 4.4 STRATEGIC INITIATIVES 36

5 REGULATORY FRAMEWORK 37

6 MARKET OVERVIEW 40

• 6.1 DRIVERS 42
  • 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 42
  • 6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 42
  • 6.1.3 INCREASE IN PIPELINE PRODUCTS 43
  • 6.1.4 INCREASING GERIATRIC POPULATION 44
  • 6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 45
• 6.2 RESTRAINTS 45
  • 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 45
  • 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 46
• 6.3 OPPORTUNITIES 46
  • 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 46
  • 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 47
  • 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 47
• 6.4 CHALLENGES 47
  • 6.4.1 LIMITED ACCESS TO TREATMENT 47
  • 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 48

7 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE 49

• 7.1 OVERVIEW 50
• 7.2 WET AMD 53
  • 7.2.1 MEDICATIONS 54
    • 7.2.1.1 ANTI-VEGF THERAPY 54
    • 7.2.1.2 OTHERS 54
  • 7.2.2 SURGERY 54
• 7.3 DRY AMD 55

8 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER 56

• 8.1 OVERVIEW 57
• 8.2 HOSPITALS 60
• 8.3 SPECIALTY CLINICS 61
• 8.4 AMBULATORY SURGICAL CENTERS 61
• 8.5 HOME HEALTHCARE 62
• 8.6 OTHERS 62

9 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL 63

• 9.1 OVERVIEW 64
• 9.2 RETAIL SALES 67
  • 9.2.1 HOSPITAL PHARMACIES 68
  • 9.2.2 RETAIL PHARMACIES 68
  • 9.2.3 OTHERS 68
• 9.3 DIRECT TENDER 69

10 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION 70

• 10.1 MIDDLE EAST AND AFRICA 72
  • 10.1.1 SOUTH AFRICA 74
  • 10.1.2 SAUDI ARABIA 76
  • 10.1.3 U.A.E. 78
  • 10.1.4 ISRAEL 80
  • 10.1.5 EGYPT 82
  • 10.1.6 KUWAIT 84
  • 10.1.7 REST OF SOUTH AFRICA 86

11 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 87

• 11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 87

12 SWOT ANALYSIS 88

13 COMPANY PROFILE 89

• 13.1 REGENERON PHARMACEUTICALS INC. 89
  • 13.1.1 COMPANY SNAPSHOT 89
  • 13.1.2 REVENUE ANALYSIS 90
  • 13.1.3 COMPANY SHARE ANALYSIS 90
  • 13.1.4 PRODUCT PORTFOLIO 91
  • 13.1.5 RECENT DEVELOPMENTS 91
• 13.2 BAYER AG 92
  • 13.2.1 COMPANY SNAPSHOT 92
  • 13.2.2 REVENUE ANALYSIS 92
  • 13.2.3 COMPANY SHARE ANALYSIS 93
  • 13.2.4 PRODUCT PORTFOLIO 93
  • 13.2.5 RECENT DEVELOPMENT 94
• 13.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD) 95
  • 13.3.1 COMPANY SNAPSHOT 95
  • 13.3.2 COMPANY SHARE ANALYSIS 95
  • 13.3.3 PRODUCT PORTFOLIO 96
  • 13.3.4 RECENT DEVELOPMENT 96
• 13.4 NOVARTIS AG 97
  • 13.4.1 COMPANY SNAPSHOT 97
  • 13.4.2 REVENUE ANALYSIS 97
  • 13.4.3 COMPANY SHARE ANALYSIS 98
  • 13.4.4 PRODUCT PORTFOLIO 98
  • 13.4.5 RECENT DEVELOPMENTS 99
    • 13.4.5.1 AGREEMENT 99
• 13.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.) 100
  • 13.5.1 COMPANY SNAPSHOT 100
  • 13.5.2 REVENUE ANALYSIS 100
  • 13.5.3 COMPANY SHARE ANALYSIS 101
  • 13.5.4 PRODUCT PORTFOLIO 101
  • 13.5.5 RECENT DEVELOPMENT 102
• 13.6 ADVERUM BIOTECHNOLOGIES, INC. 103
  • 13.6.1 COMPANY SNAPSHOT 103
  • 13.6.2 PRODUCT PORTFOLIO 103
  • 13.6.3 RECENT DEVELOPMENT 104
• 13.7 BIOGEN 105
  • 13.7.1 COMPANY SNAPSHOT 105
  • 13.7.2 PRODUCT PORTFOLIO 105
  • 13.7.3 RECENT DEVELOPMENT 105
• 13.8 GENSIGHT BIOLOGICS 106
  • 13.8.1 COMPANY SNAPSHOT 106
  • 13.8.2 REVENUE ANALYSIS 106
  • 13.8.3 PRODUCT PORTFOLIO 107
  • 13.8.4 RECENT DEVELOPMENTS 107
• 13.9 IONIS PHARMACEUTICALS 108
  • 13.9.1 COMPANY SNAPSHOT 108
  • 13.9.2 REVENUE ANALYSIS 108
  • 13.9.3 PRODUCT PORTFOLIO 109
  • 13.9.4 RECENT DEVELOPMENTS 109
• 13.10 JOHNSON &JOHNSON SERVICES, INC. 110
  • 13.10.1 COMPANY SNAPSHOT 110
  • 13.10.2 REVENUE ANALYSIS 110
  • 13.10.3 PRODUCT PORTFOLIO 111
  • 13.10.4 RECENT DEVELOPMENTS 111
• 13.11 KODIAK SCIENCES INC. 113
  • 13.11.1 COMPANY SNAPSHOT 113
  • 13.11.2 PRODUCT PORTFOLIO 113
  • 13.11.3 RECENT DEVELOPMENTS 113
• 13.12 MEIRAGTX LIMITED 114
  • 13.12.1 COMPANY SNAPSHOT 114
  • 13.12.2 PRODUCT PORTFOLIO 114
  • 13.12.3 RECENT DEVELOPMENTS 114 
• 13.13 OCUGEN, INC. 116
  • 13.13.1 COMPANY SNAPSHOT 116
  • 13.13.2 PRODUCT PORTFOLIO 116
  • 13.13.3 RECENT DEVELOPMENTS 117
• 13.14 OUTLOOK THERAPEUTICS, INC. 118
  • 13.14.1 COMPANY SNAPSHOT 118
  • 13.14.2 PRODUCT PORTFOLIO 118
  • 13.14.3 RECENT DEVELOPMENT 118
• 13.15 REGENXBIO INC. 119
  • 13.15.1 COMPANY SNAPSHOT 119
  • 13.15.2 PRODUCT PORTFOLIO 119
  • 13.15.3 RECENT DEVELOPMENTS 120
• 13.16 SYLENTIS, S.A. 121
  • 13.16.1 COMPANY SNAPSHOT 121
  • 13.16.2 PRODUCT PORTFOLIO 121
  • 13.16.3 RECENT DEVELOPMENT 121

14 QUESTIONNAIRE 122

15 RELATED REPORTS 125

LIST OF TABLES

• TABLE 1 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 53
• TABLE 2 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 53
• TABLE 3 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 53
• TABLE 4 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 54
• TABLE 5 MIDDLE EAST AND AFRICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 55
• TABLE 6 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 60
• TABLE 7 MIDDLE EAST AND AFRICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION) 60
• TABLE 8 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 61
• TABLE 9 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 61
• TABLE 10 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 62
• TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 62
• TABLE 12 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 67
• TABLE 13 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 67
• TABLE 14 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 68
• TABLE 15 MIDDLE EAST AND AFRICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 69
• TABLE 16 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 72
• TABLE 17 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 72
• TABLE 18 MIDDLE EAST AND AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 72
• TABLE 19 MIDDLE EAST AND AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 73
• TABLE 20 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 73
• TABLE 21 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 73
• TABLE 22 MIDDLE EAST AND AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 73
• TABLE 23 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 74
• TABLE 24 SOUTH AFRICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 74
• TABLE 25 SOUTH AFRICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 74
• TABLE 26 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 74
• TABLE 27 SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 75
• TABLE 28 SOUTH AFRICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 75
• TABLE 29 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
• TABLE 30 SAUDI ARABIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
• TABLE 31 SAUDI ARABIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
• TABLE 32 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 76
• TABLE 33 SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 77
• TABLE 34 SAUDI ARABIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 77
• TABLE 35 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
• TABLE 36 U.A.E. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
• TABLE 37 U.A.E. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
• TABLE 38 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 78
• TABLE 39 U.A.E. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 79
• TABLE 40 U.A.E. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 79
• TABLE 41 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
• TABLE 42 ISRAEL WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
• TABLE 43 ISRAEL MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
• TABLE 44 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 80
• TABLE 45 ISRAEL AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 81
• TABLE 46 ISRAEL RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 81
• TABLE 47 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
• TABLE 48 EGYPT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
• TABLE 49 EGYPT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
• TABLE 50 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 82
• TABLE 51 EGYPT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 83
• TABLE 52 EGYPT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 83
• TABLE 53 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
• TABLE 54 KUWAIT WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
• TABLE 55 KUWAIT MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
• TABLE 56 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 84
• TABLE 57 KUWAIT AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 85
• TABLE 58 KUWAIT RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 85
• TABLE 59 REST OF SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 86

LIST OF FIGURES

• FIGURE 1 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 17
• FIGURE 2 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION 20
• FIGURE 3 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS 21
• FIGURE 4 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 22
• FIGURE 5 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS 22
• FIGURE 6 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING 23
• FIGURE 7 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS 25
• FIGURE 8 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID 26
• FIGURE 9 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID 27
• FIGURE 10 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS 28
• FIGURE 11 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 31
• FIGURE 12 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 32
• FIGURE 13 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031 32
• FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET 41
• FIGURE 15 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023 50
• FIGURE 16 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION) 51
• FIGURE 17 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031) 51
• FIGURE 18 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE 52
• FIGURE 19 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023 57
• FIGURE 20 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION) 58
• FIGURE 21 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031) 58
• FIGURE 22 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE 59
• FIGURE 23 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023 64
• FIGURE 24 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 65
• FIGURE 25 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 65
• FIGURE 26 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 66
• FIGURE 27 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023) 71
• FIGURE 28 MIDDLE EAST AND AFRICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 87